Rabbit Recombinant Monoclonal GLP-1 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Glucagon. Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Glucagon-like peptide 1. Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable). Glucagon-like peptide 2. Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin. Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin. May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.
Pro-glucagon, GCG
Rabbit Recombinant Monoclonal GLP-1 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
GLP-1 also known as glucagon-like peptide-1 is a 30 or 31 amino acid peptide with a mass of approximately 3.3 kDa. This peptide is mainly secreted by intestinal L-cells and the CNS. It enhances the secretion of insulin in response to glucose making it an important regulator of blood sugar levels. GLP-1 is degraded by dipeptidyl peptidase-4 which rapidly reduces its activity. Researchers often target GLP-1 in studies aimed at understanding metabolic processes and developing therapeutic interventions.
GLP-1 influences several physiological functions by acting on its receptor GLP-1R a G-protein coupled receptor. It is not part of a complex but exerts its effects through binding to this receptor. Activation of GLP-1R promotes insulin secretion suppresses glucagon release slows gastric emptying and promotes satiety. This makes GLP-1 an important regulator in energy homeostasis and nutrient absorption. Its effects on appetite and food intake are of particular interest in obesity research.
GLP-1 is an essential component of the incretin pathway which regulates insulin secretion in response to food intake. The interaction between GLP-1 and the GLP-1 receptor activates the adenylate cyclase pathway leading to increased cAMP and PKA signaling in pancreatic beta-cells. This chain of events enhances the insulin-secreting ability of these cells. Furthermore GLP-1 has connections with proteins such as insulin and glucagon through its regulatory functions in glucose metabolism.
GLP-1 is highly relevant to type 2 diabetes and obesity. Its ability to enhance insulin secretion and promote weight loss has made it a target for drug development in the treatment of these conditions. Antidiabetic medications including GLP-1 receptor agonists exploit this mechanism to control blood sugar levels effectively. Additionally GLP-1's connection to insulin makes it a significant focus in diabetes research as imbalances in these proteins contribute to the disease pathology.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com